nathalie_moll

EFPIA names first female Director General

pharmafile | February 27, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EFPIA 

Industry trade organisation the European Federation of Pharmaceutical Industries and Associations (EFPIA) has announced the appointment of Nathalie Moll as its new Director General.

Moll currently serves as the Secretary General of the European Association for Bioindustries (EuropaBio), a position she has held for six years, and has also served the European Commission and the Italian Biotech Industry Association.

She is due to step into the role in April this year, when she will become the company’s first ever female Director General. Eric Cornut, who stepped in to carry the vacancy left by Richard Bergström last year, will fill the role on an interim basis until that time.

Joe Jimenez, Novartis CEO and President of EFPIA commented on Moll’s appointment: “Nathalie has an excellent track record of leadership and engagement across the life science sector. We are confident she is the right person to lead EFPIA, working with stakeholders to address the challenges faced by healthcare systems in Europe.” 

Moll herself remarked: “I am delighted to be joining EFPIA at a time when pharmaceutical innovation is having such a dramatic effect on the lives of patients across Europe. I look forward to working with EFPIA Members, staff and the wider research, healthcare and policy community to foster an environment that supports continued innovation and drives better outcomes for patients.”

Related Content

uk_location_in_the_eu_2016

Pharma industry calls for EMA relocation by June in open EFPIA letter

Heads of research from 19 of the biggest players in the industry have called for …

nathalie_moll

EFPIA names new first female Director General Nathalie Moll

Industry trade organisation the European Federation of Pharmaceutical Industries and Associations (EFPIA) has announced the …

pillsphotos1

The Pharmafocus debate: Is the price of new hepatitis C treatments fair?

YES – says Richard Bergström, director general of the European Federation of Pharmaceutical Industries and …

Latest content